SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (258)1/7/1999 9:36:00 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 579
 
OK..... these interesting molecules continue to advance in the clinic. Lots of interesting wording, both in this release and ass'd with the PR -------> latest Parkinson's trial.

Wish we'd get news from BMY.



To: Rudy Saucillo who wrote (258)1/7/1999 11:38:00 AM
From: lrb  Read Replies (2) | Respond to of 579
 
<<After repeat dose testing in normal subjects, SIB-1553A continues to be well-tolerated
and shows evidence of positive behavioral effects. On the basis of the behavioral effects
observed in normal subjects ...>>

Can someone help me understand what "positive behavioral effects in normal subjects"
means (or might mean)?

--lrb


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News